Clinical Trials Directory

Trials / Unknown

UnknownNCT02647164

The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring

Status
Unknown
Phase
Study type
Observational
Enrollment
360 (estimated)
Sponsor
GenoSaber · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The time of CTC and carcinoembryonic antigen(CEA) detection is baseline, 2\~7 days, 3 months, 6 months, 12 months, 24 months, 36 months after the surgery. And the time of CT detection is 6 months, 12 months, 24 months, 36 months after the surgery.

Conditions

Timeline

Start date
2016-01-01
Primary completion
2018-09-01
First posted
2016-01-06
Last updated
2016-01-06

Source: ClinicalTrials.gov record NCT02647164. Inclusion in this directory is not an endorsement.

The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring (NCT02647164) · Clinical Trials Directory